Metrics as of 10/15/2026, 11:33 AM (Berlin time), refresh in progress.
REGENXBIO Stock
REGENXBIO Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Curran Simpson
- Employees
- 371
- Market cap
- $454 M
- IPO
- 17/09/2015
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to…
REGENXBIO stock: price history
1D
-5.2%
1W
-9.5%
1M
-20.8%
6M
-26.5%
YTD
-52.2%
1Y
-38.8%
2Y
-32.5%
5Y
-80.9%
10Y
-57.1%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~43% stronger price swings than usual
Ask the agents about REGENXBIO
Analyst assessment of REGENXBIO
PRICE TARGET LOW
US$12.00
CONSENSUS
US$20.00
MEDIAN
US$19.50
PRICE TARGET HIGH
US$29.00
1
STRONG BUY
12
BUY
6
HOLD
1
SELL
0
STRONG SELL
20
TOTAL · Buy
As of: 25/08/2026
REGENXBIO stock metrics
P/E
-1.82
P/B
5.06
EV/EBITDA
-3.5
RETURN ON EQUITY
31.6%
NET MARGIN
21.0%
DEBT/EQUITY
0.96
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
86.7%
FLOAT SHARES
57,230,797
AVG. DAILY VOLUME (30D)
1,429,378
Insider transactions (SEC)
Malzahn Craig
Chan Mitchell
Ciongoli Gregory Austin
Ciongoli Gregory Austin
Ciongoli Gregory Austin
Institutional holders
Comparable stocks
Frequently asked questions about REGENXBIO stock
What does REGENXBIO do?
REGENXBIO Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Curran Simpson, the company employs around 371 people.
The IPO was on 17/09/2015; the stock trades on NASDAQ under the ticker RGNX.
What do analysts say about REGENXBIO stock?
20 analysts rate the stock, the consensus is Buy (as of 25/08/2026).
The average price target is US$20.00, ranging from US$12.00 to US$29.00, with a median of US$19.50.
This is an external assessment, not a statement by Market Jury.
When does REGENXBIO report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 43% stronger than usual.
Does REGENXBIO pay a dividend?
No, REGENXBIO currently does not pay a dividend.
Which stocks are comparable to REGENXBIO?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get REGENXBIO stock analyzed?
Clicking "Analyze stock" lets five strategies assess REGENXBIO against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.